Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Launch excellence: five critical areas

By Jonathan Carney

- PMLiVE

New syndicated COPD report now available

Living with COPD 2023

Inizio

Increased Timeliness for yor Advisory Boards

We've broken down the top ten benefits of why virtual advisory boards are superior to in-person and hybrid advisory boards. #3. Increased Timeliness to Insight-gathering and Output Delivery Based on...

Impetus Digital

- PMLiVE

Medscape Medical Affairs Selected as Finalist for 2023 Pharmaceutical Market Excellence Awards (PMEAs)

We’re delighted to announce that two Global Medscape Medical Affairs programmes have been shortlisted in various categories for The Pharmaceutical Market Excellence Awards (PMEAs). The two programmes selected both succeeded...

Medscape Medical Affairs

- PMLiVE

Takeda announces EC approval for Adcetris combination in Hodgkin lymphoma

The ADC has been approved alongside doxorubicin, vinblastine and dacarbazine

- PMLiVE

Scientists discover way to reverse drug resistance in prostate cancer

Targeting ‘hijacked’ white blood cells could reverse drug resistance and slow tumour progression

- PMLiVE

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

Non-small cell lung cancer represents approximately 85% of all lung cancer cases

- PMLiVE

The hidden value of patient engagement in pharmaceutical development

By Su Smith

- PMLiVE

Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient

As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.

Avalere Health

- PMLiVE

Roche and Monte Rosa enter molecular glue degrader partnership worth over $2bn

The companies will work on therapies for targets in cancer and neurological diseases

- PMLiVE

FDA approves UCB’s inflammatory disease drug Bimzelx for plaque psoriasis

More than 7.5 million adults in the US are affected by some form of the chronic inflammatory condition

- PMLiVE

AstraZeneca studies highlight burden of COVID-19 for immunocompromised

The risk of hospitalisation due to COVID-19 was 14 times greater for IC individuals

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links